慢性肾脏病合并症状性颈动脉狭窄患者颈动脉支架术的单中心回顾性研究
该单中心回顾性研究纳入1363例接受颈动脉支架术的症状性颈动脉狭窄患者,按肾小球滤过率分为CKD 2至5期。主要终点为10年随访期内卒中、心肌梗死或死亡的无事件生存期。结果显示CKD 2-3期患者长期无事件生存获益较好,而4-5期患者长期无事件生存期显著降低,10年无事件生存率分别为78.0%、70.4%、54.8%和36.3%。
要点
- CKD 2-3期症状性颈动脉狭窄患者接受CAS可获得较好的长期无事件生存。
- CKD 4-5期患者CAS术后长期无事件生存期显著降低,需谨慎评估获益风险。
- 围手术期事件率随CKD分期加重而升高,4期达10.3%,5期为8.7%。
核心结论
- CKD 2-3期患者从侵入性CAS中获得长期无事件生存获益。
- CKD 4-5期患者长期无事件生存期差或预期寿命缩短,限制了10年随访期间的事件预防。
- 即使对有症状的患者,计划CAS时也需谨慎考虑潜在获益。
研究设计与样本
- 单中心回顾性研究,纳入1363例接受CAS的症状性颈动脉狭窄患者。
- 按肾小球滤过率将患者分为CKD 2、3、4、5期共4组。
- 主要终点为10年随访期内卒中、心肌梗死或死亡的无事件生存期。
- 次要结局为CAS后30天内围手术期主要不良事件,包括任何卒中、心肌梗死、死亡或短暂性脑缺血发作。
主要发现
- 围手术期事件率在4组中分别为1.8%、3.0%、10.3%和8.7%。
- 3年无事件生存率分别为96.1%、86.7%、78.4%和63.5%。
- 5年无事件生存率分别为91.0%、80.2%、65.2%和49.5%。
- 10年无事件生存率分别为78.0%、70.4%、54.8%和36.3%。
- Kaplan-Meier分析显示CKD 2期与3期长期无事件生存期无差异(107.79个月,95%CI 104.64-110.95 vs 97.20个月,95%CI 90.71-103.69),而4期与5期无事件生存期更低(67.04个月,95%CI 61.15-72.93 vs 58.56个月,95%CI 48.20-68.91)(log-rank P < .001)。
临床怎么用
- 临床可按CKD分期对CAS候选者进行分层:2-3期患者推荐CAS以获得较好的长期无事件生存。
- 对4-5期患者,干预前需进行谨慎的个体化获益-风险评估。
- 应避免对预期寿命有限的晚期CKD患者过度治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the short- and long-term event-free survival (EFS) in patients with chronic kidney disease (CKD) undergoing carotid artery stenting (CAS) for the treatment of symptomatic carotid artery stenosis. METHOD: The single-center retrospective study included 1363 patients, who were categorized into CKD stages 2, 3, 4, and 5 based on their glomerular filtration rate. The primary endpoint was long-term EFS from the occurrence of stroke, myocardial infarction (MI), or death within a 10-year follow-up period. Secondary outcomes included perioperative major adverse events, such as any stroke, MI, death, or transient ischemic attacks (TIAs) occurring within 30 days after CAS. RESULTS: Perioperative event rates were 1.8%, 3.0%, 10.3%, and 8.7% across the 4 cohorts. The estimated rates of EFS were 96.1% versus 86.7% versus 78.4% versus 63.5% at 3 years, 91.0% versus 80.2% versus 65.2% versus 49.5% at 5 years and 78.0% versus 70.4% versus 54.8% versus 36.3% at 10 years. Kaplan-Meier analysis reported that the long-term EFS did not differ between patients with stage 2 and stage 3 CKD (107.79 months 95% confidence interval [CI]: 104.64, 110.95 vs 97.20 months, 95% CI, 90.71-103.69), whereas EFS was lower in patients with stage 4 and stage 5 CKD (67.04 months, 95% CI, 61.15-72.93 vs 58.56 months, 95% CI, 48.20-68.91) (log-rank P < .001). CONCLUSION: Patients with stage 2 to 3 CKD benefited from long-term EFS following invasive CAS. In contrast, those with stage 4 to 5 CKD exhibited poor long-term EFS or reduced life expectancy limiting the prevention of events over a 10-year follow-up period. Cautious consideration of the potential benefits was necessary when planning CAS even in symptomatic cases.Clinical ImpactThis study provided real-world 10-year follow-up evidence to refine CAS decision-making for symptomatic carotid stenosis patients with CKD. Clinicians could stratify candidates by CKD stages: stage 2-3 patients were recommended for CAS to gain satisfying long-term event-free survival, while for stage 4-5 patients, cautious, individualized benefit-risk assessment was required before intervention. The innovation lied in its large-sample, stage-stratified long-term outcome data filling the relevant gap in Chinese CKD population, guiding clinicians to avoid over-treatment for advanced CKD patients with limited life expectancy.
引用
- Liu S, Liu S, Chen J, et al. Carotid Artery Stenting in Symptomatic Carotid Stenosis With Chronic Kidney Disease: A Single-Center Retrospective Study. J Endovasc Ther. 2026. PMID: 42623267. doi:10.1177/15266028261479105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。